Immunotherapy for Colorectal Cancer
On this page
What is Immunotherapy for Colorectal Cancer?
Immunotherapy for colorectal cancer involves medicines that help the body's immune system recognize and destroy cancer cells more effectively. This treatment primarily benefits patients whose tumors exhibit specific genetic changes such as mismatch-repair deficiency (dMMR) or high microsatellite instability (MSI-H). Immune checkpoint inhibitors—including drugs like pembrolizumab and nivolumab—restore immune response by blocking proteins that cancer cells use to evade immune attack.
Types of Immunotherapy for Colorectal Cancer
- Immune checkpoint inhibitors (ICIs)Target PD-1, PD-L1, and CTLA-4 pathways, activating immune cells. Approved ICIs include pembrolizumab, nivolumab, and ipilimumab, mostly for MSI-H/dMMR metastatic colorectal cancer.
- Cell therapiesExperimental approaches expanding tumor-infiltrating lymphocytes to enhance immunity.
- Combination therapiesUsing ICIs with chemotherapy, radiation, or targeted agents to improve effectiveness, especially in microsatellite stable (MSS) tumors resistant to monotherapy.
When Immunotherapy is Indicated
Immunotherapy is approved for patients with advanced or metastatic colorectal cancer who have MSI-H or dMMR tumor profiles. Clinical trials are ongoing to explore its use in earlier-stage disease and combination regimens to overcome resistance in MSS tumors.
Immunotherapy Treatment Process
Immunotherapy is administered via intravenous infusion in outpatient settings, usually every few weeks. Treatment continues until disease progression or unacceptable toxicity. Generally well tolerated, but close monitoring is essential.
Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.
Benefits and Risks
Benefits of Immunotherapy for Colorectal Cancer
Durable responses and long-term remission in eligible patients
Novel mechanism differing from chemotherapy and targeted therapy
Potentially fewer side effects compared to traditional chemotherapy
Side Effects and Risks
Side effects include fatigue, rash, diarrhea, immune-related adverse events (such as inflammation of organs), and infusion-related reactions. Early recognition and management with immunosuppressants or corticosteroids is critical.
Aftercare and Recovery
Follow-up involves regular assessment of response and side effects, prompt reporting of immune-related symptoms, and supportive care to maintain quality of life.
Why Choose Everhope
Everhope Oncology offers state-of-the-art immunotherapies for colorectal cancer, including FDA-approved immune checkpoint inhibitors and clinical trial access. The program includes expert molecular profiling, personalized treatment plans, and comprehensive patient support throughout therapy.
Common questions
What is immunotherapy for colorectal cancer?
It activates the immune system to attack tumor cells, effective mainly in MSI-H/dMMR tumors.
What are the types of immunotherapy for colorectal cancer?
Primarily immune checkpoint inhibitors and experimental cell therapies, often given with other treatments.
What is the cost of immunotherapy for colorectal cancer?
Costs vary by therapy type, location, and insurance; assistance programs may help.
What are the side effects of immunotherapy for colorectal cancer?
Fatigue, rash, diarrhea, and immune-related inflammation of organs; these can be serious but manageable.
How is immunotherapy given for colorectal cancer?
Through intravenous infusions every few weeks in outpatient clinics.
What are the benefits of immunotherapy?
Durable responses, potential long-term remission, and a unique mode of action compared to chemo or targeted therapies.
Are there advances in immunotherapy for colorectal cancer?
Yes, ongoing trials explore combinations and new immune therapies to broaden benefits.